These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18000490)

  • 1. Relapse prevention in schizophrenia - new therapeutic challenges.
    Kucukalić A; Dzubur-Kulenović A; Mehmedika-Suljić E
    Psychiatr Danub; 2007 Dec; 19(4):362-6. PubMed ID: 18000490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.
    Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders
    Aust N Z J Psychiatry; 2005; 39(1-2):1-30. PubMed ID: 15660702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
    Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
    Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():41-5. PubMed ID: 9766619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.
    Kane JM; Aguglia E; Altamura AC; Ayuso Gutierrez JL; Brunello N; Fleischhacker WW; Gaebel W; Gerlach J; Guelfi JD; Kissling W; Lapierre YD; Lindström E; Mendlewicz J; Racagni G; Carulla LS; Schooler NR
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):55-66. PubMed ID: 9452941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection and intervention in schizophrenia.
    Linszen DH; Dingemans PM; Lenior ME; Scholte WF; de Haan L; Goldstein MJ
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S31-4. PubMed ID: 9690968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iatrogenic disorders associated with conventional vs. atypical antipsychotics.
    Nasrallah HA; Mulvihill T
    Ann Clin Psychiatry; 2001 Dec; 13(4):215-27. PubMed ID: 11958363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.